Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.72 |
| ▸ | HTT | P42858 | 2/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | CA5A | P35218 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29342459 | 0.89 | SIGMAR1 (0.66) | SMN1; SMN2HTTALDH1A1SIGMAR1TAAR1 | |
| SCHEMBL10815976 | 0.87 | SIGMAR1 (0.60) | SMN1; SMN2HTTALDH1A1SIGMAR1TAAR1 | |
| SCHEMBL15980805 | 0.84 | SMN1; SMN2 (0.54) | SMN1; SMN2HTTMAPTCA12CA1 | |
| SCHEMBL22292106 | 0.84 | SMN1; SMN2 (0.76) | SMN1; SMN2HTTALDH1A1MAPTCA12 | |
| SCHEMBL19505658 | 0.84 | HTT (1.00) | SMN1; SMN2HTTMAPTCA12CA1 | |
| SCHEMBL16075057 | 0.83 | ACACB (0.52) | SMN1; SMN2HTTALDH1A1SIGMAR1KDM4E | |
| SCHEMBL30797608 | 0.82 | SMN1; SMN2 (0.73) | SMN1; SMN2HTTMAPTCA12CA1 | |
| SCHEMBL15980804 | 0.82 | SMN1; SMN2 (0.51) | SMN1; SMN2HTTMAPTCA12CA1 | |
| SCHEMBL12312565 | 0.80 | SLC2A1 (0.63) | SMN1; SMN2HTTSIGMAR1 | |
| SCHEMBL278630 | 0.80 | CASR (0.58) | SMN1; SMN2HTTALDH1A1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117327050-A | Bimetal synergistic promotion system and application thereof in asymmetric synthesis of (S, S) -TBAJ-587 | 上海交通大学 | 2024-01-02 | — | — | CN | disclosed |
| US-11826350-B2 | Proline-based neuropeptide FF receptor modulators | RESEARCH TRIANGLE INSTITUTE (US) | 2023-11-28 | — | — | US | disclosed |
| US-11826350-B2 | Proline-based neuropeptide FF receptor modulators | RESEARCH TRIANGLE INSTITUTE (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230181747-A1 | DRUG LOADED PEPTIDE BRUSH POLYMERS | NORTHWESTERN UNIVERSITY (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230181747-A1 | DRUG LOADED PEPTIDE BRUSH POLYMERS | NORTHWESTERN UNIVERSITY (US) | 2023-06-15 | — | — | US | disclosed |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | NUVATION BIO INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-10730903-B2 | Adenosine analogs as methyltransferase inhibitors for treating cancer | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2020-08-04 | — | — | US | disclosed |
| US-20200231570-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2020-07-23 | — | — | US | disclosed |
| US-20200030287-A1 | PROLINE-BASED NEUROPEPTIDE FF RECEPTOR MODULATORS | RESEARCH TRIANGLE INSTITUTE | 2020-01-30 | — | — | US | disclosed |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-01-24 | — | — | US | disclosed |
| US-20090325962-A1 | TYROSINE DERIVATIVE | GENENTECH, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090325962-A1 | TYROSINE DERIVATIVE | GENENTECH, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-7595399-B2 | Tyrosine derivatives | GENENTECH, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-7595399-B2 | Tyrosine derivatives | GENENTECH, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-7557143-B2 | Thyroid receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| US-7557143-B2 | Thyroid receptor ligands | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | GENENTECH, INC. (US) | 2008-03-27 | — | — | US | disclosed |
| US-20070197522-A1 | Dpp-iv inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2007-08-23 | — | — | US | disclosed |
| US-7166600-B2 | Thiocarbamate inhibitors of alpha-4 integrins | GENENTECH, INC. (US) | 2007-01-23 | — | — | US | disclosed |
| US-7166600-B2 | Thiocarbamate inhibitors of alpha-4 integrins | GENENTECH, INC. (US) | 2007-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325962-A1 | TYROSINE DERIVATIVE | VCAM1, ICAM1, ITGB4 | SMN1; SMN2 4604/4885HTT 4593/4885ALDH1A1 401/4885 |
| US-20230181747-A1 | DRUG LOADED PEPTIDE BRUSH POLYMERS | GRPR, LNPEP, ADM2 | SMN1; SMN2 2589/4885HTT 1221/4885ALDH1A1 3527/4885 |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | SMN1; SMN2 4476/4885HTT 3160/4885ALDH1A1 2100/4885 |
| US-20200030287-A1 | PROLINE-BASED NEUROPEPTIDE FF RECEPTOR MODULATORS | NPFFR1, NPFFR2, NPBWR1 | SMN1; SMN2 1704/4885HTT 1324/4885ALDH1A1 3691/4885 |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | ADORA2A, ADORA3, ADORA1 | SMN1; SMN2 4476/4885HTT 3160/4885ALDH1A1 2100/4885 |
| US-20070197522-A1 | Dpp-iv inhibitors | DPP7, DPP4, DPP3 | SMN1; SMN2 4274/4885HTT 3749/4885ALDH1A1 2070/4885 |
| US-20200231570-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | SMN1; SMN2 4476/4885HTT 3160/4885ALDH1A1 2100/4885 |
| US-11826350-B2 | Proline-based neuropeptide FF receptor modulators | NPFFR1, NPFFR2, NPBWR1 | SMN1; SMN2 1704/4885HTT 1324/4885ALDH1A1 3691/4885 |
| US-20080075719-A1 | Method for Augmenting B Cell Depletion | CD22, ITGAM, FCGR3B | SMN1; SMN2 3548/4885HTT 4876/4885ALDH1A1 1424/4885 |
| US-10730903-B2 | Adenosine analogs as methyltransferase inhibitors for treating cancer | DIMT1, TPMT, MTAP | SMN1; SMN2 2363/4885HTT 4615/4885ALDH1A1 325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.